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Abstract
Background Cataract surgery is the most common operation performed worldwide. A fixed topical corticosteroid-antibiotic
combination is usually prescribed in clinical practice for 2 or more weeks to treat post surgical inflammation and prevent
infection. However, this protracted schedule may increase the incidence of corticosteroid-related adverse events and notably
promote antibiotic resistance.
Methods This International, multicentre, randomized, blinded-assessor, parallel-group clinical study evaluated the non-
inferiority of 1-week levofloxacin/dexamethasone eye drops, followed by 1-week dexamethasone alone, vs. 2-week gold-
standard tobramycin/dexamethasone (one drop QID for all schedules) to prevent and treat ocular inflammation and prevent
infection after uncomplicated cataract surgery. Non-inferiority was defined as the lower limit of the 95% confidence interval
(CI) around a treatment difference >–10%. The study randomized 808 patients enrolled in 53 centres (Italy, Germany, Spain
and Russia). The primary endpoint was the proportion of patients without anterior chamber inflammation on day 15 defined
as the end of treatment. Endophthalmitis was the key secondary endpoint. This study is registered with EudraCT code: 2018-
000286-36.
Results After the end of treatment, 95.2% of the patients in the test arm vs. 94.9% of the control arm had no signs of
inflammation in the anterior chamber (difference between proportions of patients= 0.028; 95% CI: −0.0275/0.0331). No
case of endophthalmitis was reported. No statistically significant difference was evident in any of the other secondary
endpoints. Both treatments were well tolerated.
Conclusions Non-inferiority of the new short pharmacological strategy was proven. One week of levofloxacin/dex-
amethasone prevents infection, ensures complete control of inflammation in almost all patients and may contain antibiotic
resistance.
Introduction
Cataract is the leading cause of blindness [1] and cataract
surgery may be considered the most common surgical
intervention worldwide [2–4]. As corneal incision is very
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small (3 mm or less), stitches are unnecessary and surgical
wound healing generally occurs spontaneously in <7 days.
Following cataract surgery, patients are usually treated to
control the post surgical inflammation and prevent infec-
tious complications, frequently with a fixed topical
corticosteroid-antibiotic combination [5].
Topical corticosteroids control the ocular inflammation
and may prevent cystoid macular oedema [6]. However, the
treatment duration is not standardized. Ophthalmologists
usually prescribe 2 or more weeks of therapy, often tapering
the dose. In this regard, shortening corticosteroid treatment
is convenient as the adverse reactions, including intraocular
hypertension, are dose dependent [7–9].
Regarding the infection prophylaxis, the European
Society of Cataract and Refractive Surgeons (ESCRS)
recommends the intracameral administration of cefuroxime.
However, ocular infection may occur at any time until
complete closure of the surgical wound [10–12] and for this
reason topical administration of antibiotic, although dis-
cretionary, is frequently prescribed [13]. The duration of
topical prophylaxis is also not standardized and in clinical
practice, is generally continued for at least 2 weeks. To
prolong the topical antibiotic beyond wound recovery has
no convincing justification [11, 12], may be useless, and
could promote bacterial resistance [13–18].
Based on these considerations, the current study tested
the hypothesis that, after uncomplicated cataract surgery,
treatment with an antibiotic-corticosteroid combination is
required for only 1 week, at least in the large majority of
patients.
Materials and methods
This was an international, multicentre, phase III, rando-
mized, blinded-assessor, parallel-group clinical study that
evaluated the non-inferiority of the levofloxacin+ dex-
amethasone (L-DSP) treatment (levofloxacin 5 mg/mL+
dexamethasone 1 mg/mL) eye drops for 7 days, followed by
dexamethasone eye drops (Maxidex®) for an additional
7 days vs. a standard treatment (tobramycin 3 mg/mL+
dexamethasone 1 mg/mL, Tobradex®) eye drops for
14 days.
Trial population
The study was conducted in 53 centres located in Italy,
Germany, Spain and Russia. Patients were eligible for
inclusion if they had had senile or presenile uncomplicated
cataract. Exclusion criteria were: (a) ocular conditions that,
at the discretion of the investigator, could have interfered
with the efficacy and/or safety evaluations (e.g., ocular
herpes, blepharitis, conjunctivitis, uveitis, keratitis, diabetic
retinopathy, retinal vein occlusions, retinal vasculitis, retinal
angiomatous proliferation, pseudo-exfoliation syndrome,
intraoperative floppy iris syndrome, etc.); (b) bilateral cat-
aract surgery; (c) treatment with prostaglandin analogues or
intravitreal injections of anti-VEGF (vascular endothelial
growth factor) drugs; (d) systemic diseases that could have
interfered with the results of the study (e.g., rheumatoid
arthritis, Sjögren’s syndrome, Behçet’s disease, systemic
lupus erythematosus, scleroderma with major ocular invol-
vement, etc.); (e) any condition that could have interfered
with the correct instillation of eye drops; (f) ocular surgery
in the study eye (including laser surgery) in the 3 months
before screening; (g) monocular patients; (h) visual acuity
(VA) < 20/80 in the contralateral eye; (i) contraindication to
ocular treatment with levofloxacin, tobramycin or dex-
amethasone; (j) pregnancy or breastfeeding.
Trial information was given in verbal and written formats
in the local languages. Written informed consent was pro-
vided by all patients before randomization. The protocol
was approved by the Ethics Committees of all centres.
Trial groups
Patients were randomized to one of two treatment groups in
a 1:1 ratio through an Interactive Web Response System.
Randomization was stratified by centre. Treatment began
immediately after surgery or after removal of the eye
dressing. Doses administered on the same day as surgery
(day 0) were considered additional to the full protocol
dosage regimen. As shown in Fig. S1, control visits were
performed after 3, 7 and 14 days of therapy (day 4, day 8
and day 15, end of the study, respectively) to evaluate the
time course of efficacy, compliance, safety and tolerability.
The test arm eye drops (L-DSP) were prescribed for
7 days, followed by dexamethasone eye drops alone
(Maxidex®) for an additional 7 days. The control arm was
tobramycin+ dexamethasone eye drops (Tobradex®) for
14 days. For all eye drops the dosage was one drop—four
times a day (hours 8.00, 13.00, 18.00 and 23.00 ± 30 min).
Patients recorded times of instillation in a diary, which
was collected to evaluate compliance with treatment. Phy-
sician in charge of assessing study parameters was blinded
to treatment assignment (blinded assessor) and had no
access to the randomization page of the eCRF. A separate
unblinded staff was responsible for assigning and dispen-
sing/return study products. Study treatment was dispensed
upon randomization (day 0) and on day 8.
Outcome measures
The primary outcome was the proportion of patients without
signs of anterior ocular chamber inflammation (sum of cells
and flare score= 0) assessed by slit lamp examination after
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14 days of treatment (day 15). Cells in the anterior chamber
were scored as follows: 0= no cells; 1= 1–5 cells; 2=
6–15 cells; 3= 16–30 cells; 4= >30 cells [19]. Aqueous
flare (Tyndall effect) was scored: 0= absent; 1= trace
barely detectable; 2=mild intensity (iris and lens details
clear); 3=moderate intensity (iris and lens details not
clear); 4= strong intensity (iris and lens details not visible
and fibrin in the anterior chamber) [20].
The secondary efficacy outcomes were: (a) incidence of
endophthalmitis; (b) proportion of patients without signs of
anterior ocular chamber inflammation after 3 and 7 days of
treatment; (c) conjunctival hyperaemia (scored: 0= absence
of inflammation, 1=mild inflammation, i.e. some vessels
injected, 2=moderate inflammation, i.e. diffuse injection
of vessels, but individual vessels still discernable, 3=
severe inflammation, i.e. intense injection of vessels, indi-
vidual vessels not easily discernable) [21] after 3, 7 and
14 days of treatment; (d) Total Ocular Symptoms Score
(TOSS); (e) patient-reported evaluation of three ocular
symptoms: itching/burning, hyperaemia of conjunctiva and
tearing (scored: 0= none, 1=mild, 2=moderate, 3=
severe) [22] after 3, 7 and 14 days of treatment; (f) ocular
pain/discomfort (scored: 0= absent, 1=mild, 2=moder-
ate, 3= severe) after 3, 7 and 14 days of treatment; and (g)
use of rescue therapy during treatment.
The safety outcomes were intraocular pressure (IOP),
VA analyzed using the decimal unit and adverse events.
The tolerability outcomes were: (a) global evaluation on
a four-point scale (0= no intolerability, 1=mild intoler-
ability, 2=moderate intolerability, 3=maximum intoler-
ability) and (b) ocular complaints of burning, stinging and
blurred vision on a four-point scale (0= none, 1=mild, 2
=moderate, 3= severe).
Compliance was assessed through the patient diary.
Statistical analysis
The study planned to enrol 800 patients, 400 in each
treatment group. This sample size, adjusted for an expected
dropout rate of about 10% [23], would have provided 80%
power to assess the non-inferiority of the test treatment
compared with the standard therapy at the one-sided
0.025 significance level. This sample size calculation
assumed identical 64% success rates (i.e., the proportion of
patients without signs of anterior chamber inflammation) in
the treatment groups after 14 days of treatment. The success
rates assumed are conservative as they correspond to those
observed with a less active surface corticosteroid compared
with dexamethasone [24]. Non-inferiority was defined as
the lower limit of the 95% confidence interval (CI) around a
treatment difference >−10%. Based on the literature data, a
success rate attributable to a putative placebo is ~30%
[25, 26]. Therefore, considering an expected success rate of
the test treatment of about 64% and a non-inferiority margin
of −10%, the indirect difference between the test treatment
and the putative placebo would be of about 25%. This
difference was judged as clinically relevant.
Efficacy analyses were performed on the full analysis set
(FAS), defined as all randomized patients who applied at
least one dose of study treatment. The per protocol set,
defined as all patients in the FAS without major protocol
violations, was used for supportive analyses.
Primary and secondary efficacy analyses, except for the
incidence of endophthalmitis and rescue medications, were
performed by applying the last observation carried forward
method to impute missing values if at least one post-baseline
value was available. Patients with no post-baseline evalua-
tions were considered “failures” (worst-case approach).
The primary efficacy endpoint was analyzed using a two-
group large-sample normal approximation test of propor-
tions. The non-inferiority of test treatment vs. the standard
therapy was met if the lower bound of the two-sided 95% CI
around the treatment difference was >−10%.
A sensitivity analysis was performed on the primary
efficacy endpoint by applying the worst-case approach to all
dropout patients regardless of the time of study dis-
continuation. A stratified analysis by centre was also per-
formed using the Cochran–Mantel–Haenszel test.
Descriptive statistics were performed and two-sided 95%
CIs of the difference between treatments were computed for
the secondary efficacy endpoints by applying a two-group
large-sample normal approximation test of proportions.
Safety and tolerability analyses were performed on the
Safety Set, defined as all randomized patients who applied
at least one dose of study treatment.




Group assignments, loss to follow-up and reasons for
withdrawal are summarized in Fig. S2. On 863 patients
screened for eligibility, 808 were randomized from August
2018 through November 2018.
The baseline characteristics in the FAS were similar in
the two groups as reported in Table 1. Intracameral
administration of cefuroxime was carried out in 80% of
patients in both treatment arms.
Regarding the compliance, overall adherence was high as
90.89% and 91.86% patients did not miss a dose during the
1st week of treatment in the test arm and control arm,
respectively, and 91.26% and 89.74%, respectively, during
the 2nd week.
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Age (years)—mean ± SD 72.12 ± 8.55 71.84 ± 8.64 71.98 ± 8.59
Age distribution—no. pts (%)
<65 70 (17.72) 71 (18.07) 141 (17.89)
65–74 157 (39.75) 154 (39.18) 311 (39.47)
≥75 168 (42.53) 168 (42.75) 336 (42.64)
Gender—no. pts (%)
Male 166 (42.03) 154 (39.19) 320 (40.61)
Female 229 (57.97) 239 (60.81) 468 (59.39)
Race—no. pts (%)a
White 393 (99.49) 391 (99.49) 784 (99.49)
Asian 1 (0.25) 1 (0.25) 2 (0.25)
American, Indian or
Alaska Native
1 (0.25) 0 (0.0) 1 (0.13)
Native Hawaiian or other
Pacific Islander
0 (0) 1 (0.25) 1 (0.13)
Pts with co-morbidity—no.
pts (%)
338 (85.57) 321 (81.68) 659 (83.63)
Cardiac disorders
Not ongoing 20 (5.06) 18 (4.58) 38 (4.82)
Ongoing 47 (11.90) 66 (16.79) 113 (14.34)
Vascular disorders
Not ongoing 8 (2.03) 6 (1.53) 14 (1.78)
Ongoing 232 (58.73) 229 (58.27) 461 (58.50)
Metabolism and nutrition disorders
Not ongoing – – –
Ongoing 137 (34.68) 138 (35.11) 275 (34.90)
Musculoskeletal and connective tissue disorders
Not ongoing 14 (3.54) 7 (1.78) 21 (2.66)
Ongoing 42 (10.63) 42 (10.69) 84 (10.66)
Endocrine disorders
Not ongoing 11 (2.78) 7 (1.78) 18 (2.28)
Ongoing 46 (11.65) 35 (8.91) 81 (10.28)
Slit lamp examination—no. pts (%)
No cells in anterior
chamber
395 (100.00) 393 (100.00) 788 (100.00)
Absence of aqueous flare
(Tyndall effect)
395 (100.00) 393 (100.00) 788 (100.00)
Conjunctival hyperaemia—no. pts (%)
Absence of inflammation 382 (96.71) 378 (96.18) 760 (96.45)
Mild inflammation 13 (3.29) 14 (3.56) 27 (3.43)
Moderate inflammation 0 (0.00) 1 (0.25) 1 (0.13)
Intraocular pressure (mmHg)—mean ± SD
Eye to be operated 15.16 ± 2.48 15.12 ± 2.41 15.14 ± 2.44
Eye not to be operated 14.95 ± 2.45 14.90 ± 2.35 14.93 ± 2.40
Visual acuity (decimal)—mean ± SD
Eye to be operated 0.41 ± 0.23 0.41 ± 0.26 0.41 ± 0.25
Eye not to be operated 0.74 ± 0.26 0.72 ± 0.24 0.73 ± 0.25
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As regards concomitant topical treatments, topical
NSAIDs were allowed during the study but were used in
only 8% of both the test and the control arms.
Primary outcome
As shown in Table 2 and Fig. 1a, 95.19% of the L-DSP arm
and 94.91% of the control arm had no signs of anterior
chamber inflammation at day 15. The difference of 0.028
(95% CI: [−0.027; 0.033]) between the two proportions
demonstrates the non-inferiority of the L-DSP treatment
since the lower bound of the two-sided 95% CI (−0.027) is
>−0.10. The outcomes of the sensitivity analysis are con-
sistent with those of the main analysis and are reported in
Fig. 2.
Secondary outcomes
No case of endophthalmitis was reported during the study.
The outcomes of other secondary endpoints are summarized
in Fig. 1. The proportion of patients without signs of
inflammation in the anterior chamber at days 4, 8 and 15 is
reported in Fig. 1a. The intergroup difference was equal to
−0.037 (95% CI: [−0.097; 0.024]) at day 4 and −0.012
(95% CI: [−0.060; 0.036]) at day 8.
The proportion of patients without conjunctival hyper-
aemia on days 4, 8 and 15 is reported in Fig. 1b. Hyper-
aemia was mostly mild in both groups and never severe.
The intergroup difference was 0.031 (95% CI: [−0.020;
0.083]), −0.030 (95% CI: [−0.072; 0.017]) and −0.015
(95% CI: [−0.046; 0.016]) at days 4, 8 and 15, respectively.
The proportions of patients without ocular symptoms
self-assessed through the TOSS at days 4, 8 and 15 were
comparable (Fig. 1c). Intergroup differences were equal to
0.034 (95% CI: [−0.025; 0.093]), −0.067 (95% CI:
[−0.061; 0.048]) and −0.025 (95% CI: [−0.070; 0.020]) at
days 4, 8 and 15, respectively.
Only marginal differences were seen in the proportions
of patients complaining of ocular pain and discomfort at
days 4, 8 and 15 (Fig. 1d), with intergroup differences equal
to −0.007 (95% CI: [−0.046; 0.032]), −0.005 (95% CI:
[−0.041; 0.031]) and 0.005 (95% CI: [−0.025; 0.035]) at
days 4, 8 and 15, respectively.
Only four patients (0.51%) required rescue therapy for
the operated eye, three in the L-DSP arm and one in the
Tobradex® arm.
Adverse events
Exposure to study treatment was very similar in the two
arms, both in terms of cumulative dose and mean daily dose
(Table 3).
The distribution of treatment-emergent adverse events
(TEAE) was similar in the two groups except for a slightly
higher incidence of headache in the L-DSP arm (Table 3).
Corneal oedema was the most common TEAE and was
reported in 3.29% of the L-DSP arm and 4.83% of the
Tobradex® arm, but most likely due to the surgical
procedure.
In the L-DSP arm, three patients (0.76%) reported at
least one severe adverse event. Four patients of the L-DSP
arm (1.01%) and two patients of the Tobradex® arm (0.51%)
reported serious TEAEs: three patients suffered from a
fracture after a fall, two patients (one in each arm) had a
myocardial infarction and one patient in the L-DSP arm had
a retinal detachment. None of these events were related to
treatment. Four patients in the L-DSP arm and three patients
in the Tobradex® arm discontinued treatment due to an
adverse event. Other observations related to safety (IOP,
VA and local tolerability) were very similar in the two
treatment arms (Table 3).
Discussion
Cataract surgery causes corneal trauma, ocular inflamma-
tion and ocular dryness, which, in turn, result in ocular
irritation [27, 28]. Conjunctival hyperaemia, anterior
chamber cells and flare and cystoid macular oedema are the








Cataract surgery/operated eye—no. pts (%)
Right 205 (51.90) 199 (50.64) 404 (51.27)
Left 190 (48.10) 194 (49.36) 384 (48.73)
Intracameral antibiotic
administered
316 (80.00) 315 (80.15) 631 (80.08)
Surgery completed without
complications
395 (100.00) 393 (100.00) 788 (100.00)
aRace was self-reported.
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[29]. Inflammation is usually self-limiting, but drug therapy
is routinely used in clinical practice to shorten resolution
time and alleviate ocular discomfort [30], also in relation to
the practice patterns in postoperative drug therapy published
by the American Society of Cataract Refractive Surgery,
the Canadian Ophthalmological Society and the ESCRS
[31–33]. Corticosteroid eye drops have been used to prevent
and treat ocular inflammation for decades, and dex-
amethasone is the most commonly used [32]. However, the
optimal duration of corticosteroid therapy is not defined.
The results of this study have shown that corticosteroid
treatment exerts an intense anti-inflammatory activity very
quickly both in the anterior chamber and on the ocular sur-
face. Indeed, over 70% of patients in both treatment arms had
no inflammatory signs in the anterior chamber, such as 0 cells
and 0 flare, after only 3 days. At the end of the 1st week, the
percentage of patients without inflammatory signs in the
anterior chamber was higher than 85% in both groups, and the
other patients (<15%) presented only very modest inflam-
matory signs. At the end of the 2nd week, inflammatory signs
in the anterior chamber (the main outcome) were absent in
more than 95% of patients, without significant intergroup
differences. Therefore, it is conceivable to consider that in the
clear majority of patients undergoing cataract surgery, 7 days
of corticosteroid treatment may be sufficient to completely
control anterior chamber inflammation.
Consistently, conjunctival hyperaemia was completely
controlled after 3 days of therapy in 85.3% of the L-DSP
arm and 82.2% of the control arm. After 7 days, con-
junctival hyperaemia completely regressed in over 90% of
patients in both treatment arms. Therefore, 7 treatment days
were also sufficient to completely control the post surgical
ocular surface inflammation.
It is important to underline that these anti-inflammatory
effects on anterior chamber and ocular surface were not sig-
nificantly influenced by the concomitant use of topical
NSAIDs, which was used by <10% of patients of both groups.
Therefore, to limit the risk of side effects, the prescrip-
tion of additional therapy with dexamethasone alone after
the 1-week levofloxacin/dexamethasone combination may
be limited to the very small proportion of patients who still
present signs of inflammation of such intensity as to require
further treatment. In our study, there was no tapering of the
corticosteroid treatment since the recurrence of the inflam-
matory process at the suspension of the treatment, possible
in chronic inflammatory and autoimmune diseases, is unli-
kely after a surgical trauma once the inflammation has been
completely controlled by the therapy. However, more data
are needed to understand whether reducing the duration of
corticosteroid therapy may have an impact on the incidence
of pseudophakic macular oedema (Irvine–Gass syndrome).
Regarding the prophylaxis of infections, ocular infec-
tions are largely caused by pathogens colonizing the ocular
surface [33], and may occur until the complete closure of
the surgical wound. Topical antibiotics are therefore fre-
quently used after the recommended intracameral adminis-
tration of cefuroxime [11, 34]. The preferred topical
antibiotics belong to the aminoglycoside and quinolone
families, but the latter is more active against Gram-positive








Absence of signs of
anterior chamber
inflammation (cells and
flare) at day 15—no.
pts (%)a










– (0.00) – (0.00)
Absence of signs of anterior chamber inflammation (cells and flare)
—no. pts (%)a
At day 4 289 (73.16) 302 (76.84)
At day 8 338 (85.57) 341 (86.77)
Resolution of conjunctival hyperaemia (score= 0)—no. pts (%)b
At day 4 337 (85.32) 323 (82.19)
At day 8 348 (88.10) 358 (91.09)
At day 15 371 (93.92) 375 (95.42)
Absence of ocular symptoms (TOSS= 0)—no. pts (%)c
At day 4 310 (78.48) 295 (75.06)
At day 8 320 (81.01) 321 (81.68)
At day 15 343 (86.84) 351 (89.31)
Absence of ocular pain and discomfort (score= 0)—no. pts (%)d
At day 4 360 (91.14) 361 (91.86)
At day 8 366 (92.66) 366 (93.13)
At day 15 377 (95.44) 373 (94.91)
aThe anterior chamber cell count and flare score were assessed using
slit lamp.
bConjunctival hyperaemia will be evaluated, and results provided as a
score are as follows: 0= absence of inflammation, 1=mild
inflammation (some vessels injected), 2=moderate inflammation
(diffuse injection of vessels, but individual vessels are still discern-
able), 3= severe inflammation (intense injection of vessels, individual
vessels not easily discernable).
cThe Total Ocular Symptoms Score (TOSS) is a patient-reported
evaluation of three ocular symptoms: itching/burning, hyperaemia of
conjunctiva and tearing. Each symptom is given a score: 0= none, 1
=mild, 2=moderate, 3= severe.
dOverall ocular pain and discomfort will be evaluated by the subject at
days 4, 8 and 15 on a four-point scale (0= absent, 1=mild, 2=
moderate, 3= severe).
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bacteria, frequently responsible for infections after cataract
surgery. The duration of topical antibiotic prophylaxis is not
standardized. Despite in the ESCRS prophylaxis study of
endophthalmitis, topical levofloxacin treatment lasted
6 days [35], topical antibiotics are generally continued in
clinical practice for at least 2 weeks. Moreover, to favour
Fig. 1 Primary and secondary outcomes. a Signs of anterior
chamber inflammation; b conjunctival hyperaemia; c TOSS Total
Ocular Symptoms Score; d ocular pain and discomfort. a The anterior
chamber cell count and flare score were assessed using slit lamp. b
Conjunctival hyperaemia was evaluated on a scale ranging from 0=
absence of inflammation to 3= severe inflammation. c Total Ocular
Symptoms Score (TOSS) is the sum of itching/burning, hyperaemia
and tearing scores, each symptoms scoring from 0= none to 3=
severe. d Ocular pain and discomfort were evaluated on a four-point
scale, ranging from 0= absent to 3= severe.
Fig. 2 Sensitivity analysis. Last observation carried forward (LOCF)
method was used to impute missing values if at least one post-baseline
value is available. Dropout patients with only the baseline value are
considered as ‘failures’. Worst case: dropout patients independently of
the time of dropout are considered as ‘failures’. Stratified: within each
country, centres with <10 patients randomized were pooled for the
stratified analysis. n= number of patients without signs of anterior
chamber inflammation; m= total number of patients valid in the
analysis set. Difference between treatment groups is calculated as
(levofloxacin+ dexamethasone) vs. (tobramycin+ dexamethasone).
FAS full analysis set, PP per protocol.
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patient compliance, the topical antibiotics are often admi-
nistered in a preformed combination with a corticosteroid.
Given the custom of corticosteroid tapering, the antibiotic in
fixed associations is also progressively reduced after the
initial 2 weeks. These widespread modalities of empirical
treatment must be considered irrational since the surgical
wound usually heals within 7 days [13, 14]. Therefore,
prolonging the administration of a topical antibiotic beyond
this period is not reasonable as protracted antibiotic treat-
ment, besides not being useful, could favour the appearance
of bacterial resistance, especially if tapering is performed
[15–17].
To our knowledge, this study is the first to compare two
topical antibiotic prophylaxis regimens of different dura-
tion: 7 days, justified by the mean surgical wound repair
time, vs. 14 days, which represents the average duration
implemented in clinical practice. In this study, topical pro-
phylaxis was performed independently of the intracameral
administration of cefuroxime, which although recom-
mended by the ESCRS, was not mandatory and was per-
formed in 80% of patients in both groups. During the study,
no case of endophthalmitis was observed in both arms.
Therefore, the short-term prophylaxis performed in the L-
DSP arm was not different from the protracted one imple-
mented in the Tobradex® arm. The results of the study seem
to confirm the efficacy of short antibiotic prophylaxis,
which, if implemented systematically, would lead to at least
halving the amount of antibiotic used in prophylaxis in the
most widespread surgical intervention in the world, with
undoubted advantages from the point of view of cost con-
tainment and reduction of adverse events. Furthermore, this
new short-lasting treatment strategy could represent a major
step forward in the direction of limiting the prophylactic use
of antibiotics and, consequently, the emergence of antibiotic
resistance, one of the main public health problems that will
have to be effectively addressed in the coming years.
The current study had some limitations, including the
single-blind design (however, no alternative was possible
because of the switch from a fixed combination to corti-
costeroid alone in the study arm and the different for-
mulation of the medications: L-DSP is a solution and
Tobradex® a suspension, so the blindness could not be
ensured), uncomplicated cataract as inclusion criterion, and
the number of patients enrolled in relation to the very low
incidence of endophthalmitis. In any case, the size of the
recruited sample, which is among the highest in the clinical
trials available on this specific indication, suggests that with
short-term prophylaxis the incidence of endophthalmitis is
likely to be <0.2%, and not greater than that expected in a
population partially treated with intracameral antibiotic
injection [36].












Significant increase vs. baseline of intraocular pressure (>6 mmHg) in the
operated eye—no. pts (%)
At day 4 393 5 (1.27) 393 5 (1.27)
At day 8 391 2 (0.51) 393 7 (1.78)
At day 15 389 4 (1.03) 391 2 (0.51)
Significant decrease
vs. baseline of visual
acuity in the operated
eye at day 15—no. pts
(%)a





TEAEs 56 (14.18) 51 (12.98)
Serious TEAEs 4 (1.01) 2 (0.51)
Severe TEAEs 3 (0.76) 0 (0.00)
TEAEs suspected to
be related to study
treatment




4 (1.01) 3 (0.76)
Fatal TEAEs 1 (0.25)b 0 (0.00)
Local tolerability
Global evaluation: intolerability—no. pts (%)c
At day 4 393 7 (1.78) 393 3 (0.76)
At day 8 391 5 (1.28) 393 8 (2.04)
At day 15 389 6 (1.54) 391 7 (1.79)
Burning—no. pts (%)d
At day 4 393 30 (7.63) 393 36 (9.16)
At day 8 391 21 (5.38) 393 41 (10.43)
At day 15 389 26 (6.68) 391 27 (6.91)
Stinging—no. pts (%)d
At day 4 393 19 (4.83) 393 17 (4.33)
At day 8 391 22 (5.62) 393 25 (6.36)
At day 15 389 21 (5.39) 391 16 (4.09)
Blurred vision—no. pts (%)d
At day 4 393 21 (5.34) 393 16 (4.07)
At day 8 391 22 (5.63) 393 14 (3.56)




395 3.81 ± 0.35 393 3.87 ± 0.60
aBest-corrected visual acuity (BCVA) using ETDRS chart.
bThe death was due to myocardial infarction; the Investigator did not
suspect a causal relationship between the event and study treatment.
cGlobal evaluation on a four-point scale: 0= no intolerability, 1=
mild intolerability, 2=moderate intolerability, 3=maximum
intolerability.
dBurning, stinging, blurred vision on a four-point scale: 0= none, 1=
mild, 2=moderate, 3= severe.
eEvaluated through the patient diary, in which the subject is to record
all treatments.
F. Bandello et al.
On the other hand, the present study has some strengths:
a robust methodology, a conservative sample size for the
principal endpoint (one of the highest in literature) and
high-quality findings (a very high quote of randomized
patients was analyzable and the study was completed in
<4 months).
In conclusion, this is the first randomized clinical study
showing the validity of short-term antibiotic/corticosteroid
treatment in cataract surgery. The present study suggests
that a fixed-dose ophthalmic preparation of levofloxacin and
dexamethasone may represent a judicious addition to the
current armamentarium of drugs available for the treatment/
prevention of inflammation and the prevention of infection
following cataract surgery. From a pragmatic point of view,
this study may also suggest that a follow-up visit should be
planned 1 week after surgery as it allows to identify patients
that theoretically do not need further medication if have
complete resolution of inflammation. This new short-lasting
treatment strategy could, therefore, represent both an
opportunity to optimize the use of corticosteroids after
cataract surgery and a major step forward in the direction of
limiting the prophylactic use of antibiotics and, conse-
quently, the emergence of antibiotic resistance.
Summary
What was known before
● Evidence on medical treatment after cataract surgery is
relatively limited to the duration of topical infection
prophylaxis (after the recommended intracameral
administration of cefuroxime) and of anti-inflammatory
treatment. Frequently these treatments are performed
with a fixed antibiotic/corticosteroid eye drop combina-
tion, but the duration of the administration is not
standardized. In the clinical practice, the antibiotic
prophylaxis is generally continued for at least 2 weeks,
longer than probably necessary, as surgical wound
usually repairs within 1 week. Also, the duration of
topical corticosteroids (generally 2 or more weeks, often
with a dose tapering of the fixed combination) is not
supported by clinical evidence, and shortening is
potentially convenient as the adverse reactions, includ-
ing intraocular hypertension, are dose dependent.
What this study adds
● This study provided for the first time the evidence that
1-week levofloxacin–dexamethasone eye drops were
effective as 2-week tobramycin–dexamethasone eye
drops for local prophylaxis of ocular infection: no
endophthalmitis was observed in either treatment
group. Moreover, 1-week of
levofloxacin–dexamethasone eye drops were able to
abolish ocular inflammation in 85% of patients,
showing that for a high percentage of patients it is
not necessary to prolong the corticosteroid treatment
beyond the 1st week after surgery. Based on the results
of this study, which showed that the administration of
levofloxacin–dexamethasone in fixed combination for
a single week is effective for the prophylaxis of
infections and for controlling post surgical inflamma-
tion, new strategies could be designed for patients
undergoing cataract surgery in order to save misuse of
antibiotics and consequently prevent antibiotic resis-
tance as well as to minimize steroidal side effects.
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